Search research articles
Contact Us
Filters
Showing results (1-10 of 14) with videos related to
Page
of 2
Sort By:
Translational Oncology
|
June 25, 2021
Response to "The need for validation of MI GPSai in patients with CUP: Comment on: "Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type" by J Abraham et al."
Jim Abraham, Chadi Nabhan, Matthew Oberley, et al.
Gynecologic Oncology
|
May 9, 2025
Whole-exome sequencing provides assessment of homologous recombination deficiency for identification of PARPi-responsive ovarian tumors
Elizabeth Evans, Jhalak Dholakia, Jim Abraham, et al.
Journal of the National Cancer Institute
|
August 3, 2022
Discoidin Domain Receptor-Driven Gene Signatures as Markers of Patient Response to Anti-PD-L1 Immune Checkpoint Therapy
Sungyong You, Minhyung Kim, Xen Ping Hoi, et al.
Scientific Reports
|
March 12, 2021
Pan-cancer analysis of RNA expression of ANGIOTENSIN-I-CONVERTING ENZYME 2 reveals high variability and possible impact on COVID-19 clinical outcomes
Andrew Elliott, Michelle Saul, Jia Zeng, et al.
Nature Communications
|
March 19, 2025
Real-world evidence provides clinical insights into tissue-agnostic therapeutic approvals
George W Sledge, Takayuki Yoshino, Joanne Xiu, et al.
Translational Oncology
|
January 19, 2021
Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type
Jim Abraham, Amy B Heimberger, John Marshall, et al.
JTO Clinical and Research Reports
|
September 9, 2022
Characterization of <i>MET</i> Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing
So Yeon Kim, Jun Yin, Stephen Bohlman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 13, 2024
Differential Responses to Immune Checkpoint Inhibitors are Governed by Diverse Mismatch Repair Gene Alterations
Moh'd M Khushman, Michael D Toboni, Joanne Xiu, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 2, 2022
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies
Carlotta Antoniotti, Marco M Germani, Daniele Rossini, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 8, 2021
Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study
Carlotta Antoniotti, W Michael Korn, Federica Marmorino, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 14) with videos related to
Sort By:
Page
of 2
Translational Oncology
|
June 25, 2021
Response to "The need for validation of MI GPSai in patients with CUP: Comment on: "Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type" by J Abraham et al."
Jim Abraham, Chadi Nabhan, Matthew Oberley, et al.
Gynecologic Oncology
|
May 9, 2025
Whole-exome sequencing provides assessment of homologous recombination deficiency for identification of PARPi-responsive ovarian tumors
Elizabeth Evans, Jhalak Dholakia, Jim Abraham, et al.
Journal of the National Cancer Institute
|
August 3, 2022
Discoidin Domain Receptor-Driven Gene Signatures as Markers of Patient Response to Anti-PD-L1 Immune Checkpoint Therapy
Sungyong You, Minhyung Kim, Xen Ping Hoi, et al.
Scientific Reports
|
March 12, 2021
Pan-cancer analysis of RNA expression of ANGIOTENSIN-I-CONVERTING ENZYME 2 reveals high variability and possible impact on COVID-19 clinical outcomes
Andrew Elliott, Michelle Saul, Jia Zeng, et al.
Nature Communications
|
March 19, 2025
Real-world evidence provides clinical insights into tissue-agnostic therapeutic approvals
George W Sledge, Takayuki Yoshino, Joanne Xiu, et al.
Translational Oncology
|
January 19, 2021
Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type
Jim Abraham, Amy B Heimberger, John Marshall, et al.
JTO Clinical and Research Reports
|
September 9, 2022
Characterization of <i>MET</i> Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing
So Yeon Kim, Jun Yin, Stephen Bohlman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 13, 2024
Differential Responses to Immune Checkpoint Inhibitors are Governed by Diverse Mismatch Repair Gene Alterations
Moh'd M Khushman, Michael D Toboni, Joanne Xiu, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 2, 2022
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies
Carlotta Antoniotti, Marco M Germani, Daniele Rossini, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 8, 2021
Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study
Carlotta Antoniotti, W Michael Korn, Federica Marmorino, et al.
Page
of 2